A Phase 2 Study of BMN 111 to Evaluate Safety, Tolerability, and Efficacy in Children With Achondroplasia

Phase 2CompletedNCT02055157

BioMarin Pharmaceutical35 enrolled

Overview

This is a Phase 2, open-label, sequential cohort dose-escalation study of BMN 111 in children with achondroplasia. The primary objective is to assess the safety and tolerability of daily BMN 111 administered to children with achondroplasia.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Achondroplasia

Interventions

BMN 111DRUG

BMN 111 will be administered daily for 24 months in an open-label sequential dose adjustment fashion.

Eligibility

Sex: ALLMin age: 5 YearsMax age: 14 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Parent(s) or guardian(s) are willing and able to provide written, signed informed consent * 5 to 14 years old at end of study * ACH, documented by clinical grounds, confirmed by genetic testing * At least 6-month of pretreatment growth assessment in Study 111-901 before study entry, and one standing height at least 6 months prior to screening for 111-202 * Negative pregnancy test at the Screening Visit for females ≥ 10 years old or who have begun menses * If sexually active, willing to use a highly effective method of contraception while participating in the study * Ambulatory, able to stand without assistance * Willing and able to perform all study procedures as physically possible * Parents/caregivers willing to administer daily injections to the subjects Additional inclusion Criteria Optional, Open-label Extension Phase: * Appropriate written informed consent Exclusion Criteria: * Hypochondroplasia or short stature condition other than ACH * Have any of the following: * Hypothyroidism or hyperthyroidism * Insulin-requiring diabetes mellitus * Autoimmune inflammatory disease * Inflammatory bowel disease * Autonomic neuropathy * Recent acute illness associated with volume dehydration not completely resolved prior to the first dose of study drug * Unstable condition requiring surgical intervention during the study * Growth plates have fused * Have a history of any of the following: * Renal insufficiency, defined as creatinine \> 2 mg/dl * Anemia * Baseline systolic BP \< 75 mm Hg or recurrent symptomatic hypotension or recurrent symptomatic hypotension, recurrent symptomatic orthostatic hypotension * Cardiac or vascular disease, including the following: * Cardiac dysfunction (abnormal echocardiogram \[ECHO\] including left ventricle \[LV\] mass) at Screening Visit * Hypertrophic cardiomyopathy * Pulmonary Hypertension * Congenital heart disease with ongoing cardiac dysfunction * Cerebrovascular disease * Aortic insufficiency * Clinically significant atrial or ventricular arrhythmias * Have an ECG showing any of the following: * Right or left atrial enlargement or ventricular hypertrophy * PR (period of time from the beginning of atrial depolarization until the beginning of ventricular depolarization) interval \> 200 msec * QRS (The Q, R, and S heart waves that are measured on an electrocardiogram) interval \> 110 msec * Corrected QTc-F (Measure of the corrected time between the start of the Q wave and end of the T wave in the heart's electrical cycle) \> 450 msec * Second- or third-degree atrioventricular block * Documented Vitamin D deficiency * Require any investigational agent prior to completion of study period * Have received another investigational product or investigational medical device within 30 days before the Screening visit * Use of any other investigational product or investigational medical device for the treatment of ACH or short stature * Current chronic therapy with antihypertensive medications, angiotensin-converting enzyme (ACE) inhibitors, angiotensin II receptor blockers, diuretics, beta-blockers, calcium-channel blockers, cardiac glycosides, systemic anticholinergic agents, any medication that may impair or enhance compensatory tachycardia, diuretics, or other drugs known to alter renal or tubular function * Treatment with growth hormone, IGF-1 (Insulin-like growth factor), or anabolic steroids in the previous 6 months or long-term treatment (\> 3 months) at any time * Long-term treatment (\> 1 month) with oral corticosteroids * Concomitant medication that prolongs the QT/QTc-F interval within 14 days or 5 half-lives, whichever is longer, before the Screening visit * Pregnant or breastfeeding at the Screening Visit or planning to become pregnant (self or partner) at any time during the study * Limb-lengthening or bone-related surgery \< 18 months prior to study enrollment * Had a fracture of the long bones or spine within 6 months prior to screening (except for fracture of digits or toes) * AST (Aspartate Transaminase) or ALT (Alanine Transaminase) at least 3x upper limit of normal (ULN) or total bilirubin at least 2x ULN * Evidence of severe sleep apnea requiring surgery or new initiation of CPAP (Continuous positive airway pressure). * History of malignancy and chemotherapy/radiation or currently under work-up for suspected malignancy * Known hypersensitivity to BMN 111 or its excipients * Have a condition or circumstance that, in the view of the Investigator, places the subject at high risk for poor treatment compliance or for not completing the study * Concurrent disease or condition that would interfere with study participation or safety * Have abnormal findings on baseline clinical hip exam or imaging assessments that are determined to be clinically significant as determined by the PI. * Have a history of hip surgery or severe hip dysplasia * Have a history of clinically significant hip injury in the 30 days prior to screening. * History of slipped capital femoral epiphysis or avascular necrosis of the femoral head. * Are unable to lie flat when in prone position Additional Exclusion Criteria for Optional, Open-label Extension Phase: * Use of restricted therapies during the initial 6 months of the study * Permanently discontinued BMN 111 during the initial 6 months of the study

Locations (9)

Children's Hospital & Research Center Oakland

Oakland, California, United States

Harbor - UCLA Medical Center

Torrance, California, United States

Ann and Robert H. Lurie Childrens Hospital of Chicago

Chicago, Illinois, United States

Outcomes

Primary Outcomes

Overall Summary of Adverse Events During Initial 6-Month Period

A treatment-emergent Adverse Events (TEAE) is any Adverse Events that newly appeared, increased in frequency or worsened in severity following initiation of study drug administration. Serious adverse event (SAE).

Time frame: Up to Month 6 ± 7 Days

Overall Summary of Adverse Events During Entire Study Period

Time frame: Up to Month 25 ± 7 Days

Secondary Outcomes

Change From Baseline in Annualized Growth Velocity (AGV) During Initial 6-Month

Annualized Growth Velocity at Day 183 is assessed on standing height as ((Height at Day 183 Visit - Height at Baseline Visit)/(Date at Day 183 Visit - Baseline Visit Date)) x 365.25.

Time frame: At 6 month (Day 183)

Change From Baseline in Annualized Growth Velocity (AGV) During Entire Study Period - Cohort 3 and 4

Annualized Growth Velocity at Day 183 visit is assessed on standing height as ((Height at Day 183 Visit - Height at Baseline Visit)/(Date at Day 183 Visit - Baseline Visit Date)) x 365.25.

Time frame: At month 24

Change From Baseline in Annualized Growth Velocity (AGV) During Entire Study Period - Cohort 1 and 2 Switchers

Annualized Growth Velocity at 1st visit with \>= 12 months on 15ug/kg is assessed on standing height as ((Height at 1st Visit with \>= 12 Months on 15 μg/kg - Height at 1st Visit on 15 μg/kg)/(Date of the 1st Visit with \>= 12 months on 15 μg/kg - Date of at 1st Visit on 15 μg/kg)) x 365.25.

Time frame: At month 24

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.